September 24, 2025 |
Inizio has appointed Mary-Kate McGarry as Chief Strategy & Innovation Officer and Gavin McShera as Chief Information Officer, strengthening its executive leadership to drive innovation, digital transformation, and Intelligent Commercialization™ across the health and life sciences sector.

We are proud to announce the strategic appointment of two senior executives to our leadership team – advancing innovation, operational excellence, and digital transformation across the organization.
Joining the Executive Team are Mary-Kate McGarry as Chief Strategy & Innovation Officer and Gavin McShera as Chief Information Officer. These appointments strengthen our ability to deliver Intelligent Commercialization™ – seamlessly connecting science, technology, and human expertise to unlock value across every stage of the health and life sciences journey.
Mary-Kate, who served as Vice President, Global & Corporate Strategy since 2022, now joins the Executive Team as Chief Strategy & Innovation Officer. In this role, she will lead corporate strategy, innovation, global marketing, and brand development.
Since joining Inizio in 2021, following the merger of UDG Healthcare and Huntsworth, Mary-Kate has played a pivotal role in shaping the integrated corporate strategy and aligning strategic priorities across the business. As Chief Strategy & Innovation Officer, she will accelerate our Intelligent Commercialization™ approach – harnessing innovation, strategy realization, and AI-driven transformation, with a focus on:
Prior to joining Inizio, Mary-Kate built a tenured career in management consulting, working with executive teams across healthcare, financial services, and government sectors to lead large-scale transformation and growth programs.
Gavin McShera, who has served as Inizio’s CIO since 2021, now joins our Executive Team. With three decades of global experience in technology leadership across healthcare, retail, finance, aviation, and the public sector, Gavin continues to oversee our enterprise technology strategy, while playing a broader role in shaping organizational leadership.
As CIO, Gavin oversees our enterprise technology strategy, focusing on:
Before joining UDG Healthcare in 2021, Gavin served as Group CIO at Applegreen PLC and held roles at Microsoft and as an independent consultant.
With these appointments, we reinforce our commitment to being a market-leading, trusted commercialization partner for health and life sciences companies worldwide. At Inizio, we bring together data, technology, and multidisciplinary expertise to simplify complexity, reduce risk, and deliver consistent value across the commercialization journey.
Learn more about our leadership team.
This content was provided by Inizio
Latest Content from Inizio
In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria.
In the second of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Indonesia, with...
Pegasus, the UK’s leading independent health communications consultancy, picked up the much coveted ‘Consultancy of the Year’ award at last week’s Communiqué Awards 2014, fighting off stiff competition from the...
If you can only research one ASEAN market, which one do you choose?Our Free Thinking paper investigates the opportunities for pharma in ASEAN and outlines the factors you need to...
Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.
Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.
Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.
Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding.
Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding
Oncology is arguably the most exciting area of medicine in which to be working today. Biomarkers and companion diagnostics offer incredibly valuable predictive power, which is of benefit to payers,...
